Lifeward Acquires Oramed Tech, Secures $47M Investment for Biotech Pivot
Event summary
- Lifeward is acquiring Oramed’s Protein Oral Delivery (POD™) technology, targeting the injectable drugs market.
- Oramed is taking a 49.99% equity stake in Lifeward, receiving up to $47 million in investment through equity and convertible notes.
- The transaction includes a clinical trial management agreement where Oramed will fund and manage clinical trials for POD™.
- Lifeward CEO Mark Grant, previously at Medtronic and Bristol Myers Squibb, is leading the company’s diversification strategy.
- The deal is contingent on shareholder approval and standard closing conditions.
The big picture
Lifeward’s acquisition of Oramed’s POD™ technology represents a significant strategic shift, moving the company from a pure-play MedTech provider into a diversified biomedical platform. This move aims to capitalize on the $600+ billion injectable drug delivery market, but carries inherent risks associated with biotech development and regulatory hurdles. The $47 million investment provides a runway, but the company’s ability to generate returns from its existing product lines will be crucial for sustaining this expansion.
What we're watching
- Execution Risk
- Lifeward’s ability to successfully integrate Oramed’s technology and manage clinical trials will be critical to realizing the potential upside, given Oramed’s prior Phase 3 trial failure.
- Regulatory Approval
- The success of the POD™ platform hinges on securing regulatory approval, a process that could be lengthy and uncertain, potentially impacting the timeline for commercialization.
- Financial Stability
- Whether Lifeward can achieve sustainable profitability from its existing MedTech products to support the ongoing investment in the biotech portfolio remains a key factor for long-term success.
Related topics